Thiogenesis Therapeutics Corp
Q8M
Company Profile
Business description
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company’s compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Contact
4 King Street West
Suite 401
TorontoONM5H 1B6
CANT: +1 647 846-7766
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
What next for the largest company on the ASX?
After a historic rally in 2024, what lies ahead for this overvalued banking titan?
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,013.30 | 46.70 | 0.59% |
| CAC 40 | 8,028.28 | 90.07 | 1.13% |
| DAX 40 | 22,986.82 | 419.68 | 1.86% |
| Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
| FTSE 100 | 8,632.33 | 89.77 | 1.05% |
| HKSE | 23,959.98 | 497.33 | 2.12% |
| NASDAQ | 17,754.09 | 451.07 | 2.61% |
| Nikkei 225 | 37,053.10 | 263.07 | 0.72% |
| NZX 50 Index | 12,266.25 | 57.20 | 0.47% |
| S&P 500 | 5,638.94 | 117.42 | 2.13% |
| S&P/ASX 200 | 7,789.70 | 40.60 | 0.52% |
| SSE Composite Index | 3,419.56 | 60.83 | 1.81% |